COL7A1 and renal cell carcinoma: Our study establishes a paraptosis-based two-subtype classification and four-gene prognostic signature for RCC that can reliably predicting patient survival, delineate TME characteristics, and guide personalized therapy, with COL7A1 emerging as a potential therapeutic target for advancing our understanding of paraptosis in RCC pathogenesis and optimizing treatment.